ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2312

Senescent T Cells Promote Bone Loss in Rheumatoid Arthritis

Johannes Fessler1, Rusmir Husic2, Elisabeth Lerchbaum3, Verena Schwetz3, Claudia Stiegler3, Barbara Obermayer-Pietsch3, Winfried B. Graninger4 and Christian Dejaco5, 1Rheumatology and Immunology, Medical University Graz, Graz, Austria, 2Rheumatology, Medical University Graz, Graz, Austria, 3Division of Endocrinology and Metabolism, Medical University Graz, Graz, Austria, 4Internal medicine/Rheumatology and Immunology, Medical University Graz, Graz, Austria, 5Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: osteoclastogenesis, osteoporosis and rheumatoid arthritis, pathogenesis, RANK/RANKL pathway, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: T-cell Biology and Targets in Autoimmune Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:  To study the influence of aged CD28–T cells on systemic osteoporosis in rheumatoid arthritis (RA) patients.

Methods:  Prospective, cross-sectional study on 100 patients with RA [mean age 61.9 (±SD 11.2), 75% female, median time since diagnosis 162.4 (range 0-552) months, SDAI 12.7 (±SD9.3), 81% and 50% received synthetic and/or biologic DMARDs, respectively; 24% used corticosteroids, 16% were treated with bisphosphonates]. Bone mineral density (BMD) was determined by lumbar spine (LS) and total hip DEXA and laboratory markers of bone metabolism included bone specific alkaline phosphatase, osteocalcin, osteoprotegerin, β-crosslaps and soluble RANKL. PBMCs were retrieved at the same day of BMD measurement and were stained with anti-RANKL, CD3, CD4, CD8, CD45RA, CD45RO and/or CD28 mAbs to measure surface expression of RANKL on T cells and to determine the prevalence of T cell subsets by flow cytometry. In vitroRANKL regulation assays were performed using human TNF-α (100ng/ml), IL-6 (100ng/ml), IL-15 (100ng/ml) or solid-phase anti-CD3 (10ng/ml).

Results: A reduced BMD as determined by DEXA was found in 63% of RA patients (13% with osteoporosis, 50% with osteopenia). The prevalences of aged CD4+CD28– and CD8+CD28– T cells inversely correlated with T-scores of LS (corrcoeff=-0.235, p=0.028 and corrcoeff=-0.266, p=0.012, respectively) and hip (corrcoeff=-0.235, p=0.025, corrcoeff=-0.253, p=0.016 respectively). Patients with a T-score below -1.0 tended to have higher prevalences of circulating CD4+CD28– (2.2% [0.1–41.2] vs. 0.5% (0–17.6), p=0.065) and CD8+CD28–T cells [44.8% ± 20.7 vs. 37.4% ± 20.1, p=0.134] than patients with normal bone mass. No association was found between frequencies of aged T cells and blood parameters of bone metabolism.

RANKL expression was higher in CD4+CD28– T cells (3.8% [0.2-57.9]) compared to naïve CD4+CD28+CD45RA+ (2.2% [0.2-30.5], p<0.001) and memory CD4+CD28+CD45RO+ (2.8% [0.2-38], p=0.009) T cells. In the CD8+T cell population surface expression of RANKL was higher on memory (4.4% [0.5-44.5]) compared to naïve (3.3% [0.5-41.3], p<0.001) and aged T cells (2.2% [0-20.1], p<0.001).

In cell culture experiments IL-15 and anti-CD3 stimulation increased RANKL expression on all T cell subsets. IL-15 stimulation showed largest effects on memory CD4+ and CD8+ T cells [4.5-fold and 6-fold higher expression, respectively compared to unstimulated cells, p<0.05] compared to aged [3.9-fold and 5-fold, respectively, p<0.05] and naïve T cells [1.5-fold and 3.8-fold, respectively, p<0.05]. Also, activation by anti-CD3 had the largest effect on RANKL expression on memory CD4+ and CD8+T cells [7.8-fold and 7.5-fold, respectively, p<0.05] compared to naïve [5.2-fold and 4.7-fold, respectively, p<0.05] and aged cell subsets [2.9-fold and 3.2-fold, respectively, p<0.05]. IL-6 and TNF-α had no effect on RANKL.

Conclusion:  Aged CD28– T cells are linked with the occurrence of systemic bone loss in RA. Increased expression of RANKL on CD4+CD28– T cells compared to other T cell subsets is compatible with direct stimulation of osteoclastogenesis by aged T cells in RA.


Disclosure:

J. Fessler,
None;

R. Husic,
None;

E. Lerchbaum,
None;

V. Schwetz,
None;

C. Stiegler,
None;

B. Obermayer-Pietsch,
None;

W. B. Graninger,
None;

C. Dejaco,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/senescent-t-cells-promote-bone-loss-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology